Global Biologics Market Size, Share, Production, Growth, Trends, and Forecast 2019-2026

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Biologics Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.2. Overview
4.3. Market Opportunity Map
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunity
4.5. Global Biologics Market Analysis and Forecasts, 2016–2026
4.5.1. Porter’s Analysis
4.5.2. Supply Chain Analysis
4.5.2.1. Product Manufacturers
4.5.2.2. Product Distributors
4.5.2.3. End Users
4.5.3. Market Revenue Projections (US$ Mn)
4.9. Market Outlook

5. Global Biologics Market Analysis and Forecasts, By Product
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Global Biologics Market Value Share Analysis
5.4. Market Value Forecast By Product , 2016–2026
5.4.1. Monoclonal Antibodies
5.4.2. Vaccines
5.4.3. Recombinant Hormones/Proteins
5.4.4. Cell Therapy
5.4.5. Gene Therapy
5.4.6. Others
5.5. Market Attractiveness By Product

6. Global Biologics Market Analysis and Forecasts, By Application
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Global Biologics Market Value Share Analysis
6.4. Market Value Forecast By Application , 2016–2026
6.4.1. Oncology
6.4.2. Infectious Diseases
6.4.3. Immunology
6.4.4. Autoimmune Diseases
6.4.5. Others
6.5. Market Attractiveness By Application

7. Global Biologics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Global Growth Scenario
7.3. Market Value Forecast By Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. MEA
7.4. Market Attractiveness By Country/Region

8. North America Biologics Market Analysis and Forecast
8.1. Introduction/ Key findings
8.2. Market Value Forecast By Product , 2016–2026
8.2.1. Monoclonal Antibodies
8.2.2. Vaccines
8.2.3. Recombinant Hormones/Proteins
8.2.4. Cell Therapy
8.2.5. Gene Therapy
8.2.6. Others
8.3. Market Value Forecast By Application , 2016–2026
8.3.1. Oncology
8.3.2. Infectious Diseases
8.3.3. Immunology
8.3.4. Autoimmune Diseases
8.3.5. Others
8.4. Market Value Forecast By Country , 2016–2026
8.4.1. US
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Product
8.5.2. By Application
8.5.3. By Country

9. Europe Biologics Market Analysis and Forecast
9.1. Introduction/Key Findings
9.2. Market Value Forecast By Product , 2016–2026
9.2.1. Monoclonal Antibodies
9.2.2. Vaccines
9.2.3. Recombinant Hormones/Proteins
9.2.4. Cell Therapy
9.2.5. Gene Therapy
9.2.6. Others
9.3. Market Value Forecast By Application , 2016–2026
9.3.1. Oncology
9.3.2. Infectious Diseases
9.3.3. Immunology
9.3.4. Autoimmune Diseases
9.3.5. Others
9.4. Market Value Forecast By Country , 2016–2026
9.4.1. Germany
9.4.2. UK
9.4.3. Spain
9.4.4. France
9.4.5. Italy
9.4.6. Rest of Europe
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Application
9.5.3. By Country

10. Asia Pacific Biologics Market Analysis and Forecast
10.1. Introduction/Key Findings
10.2. Market Value Forecast By Product , 2016–2026
10.2.1. Monoclonal Antibodies
10.2.2. Vaccines
10.2.3. Recombinant Hormones/Proteins
10.2.4. Cell Therapy
10.2.5. Gene Therapy
10.2.6. Others
10.3. Market Value Forecast By Application , 2016–2026
10.3.1. Oncology
10.3.2. Infectious Diseases
10.3.3. Immunology
10.3.4. Autoimmune Diseases
10.3.5. Others
10.4. Market Value Forecast By Country , 2016–2026
10.4.1. India
10.4.2. China
10.4.3. Japan
10.4.4. Australia
10.4.5. New Zealand
10.4.6. Rest of Asia Pacific
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Application
10.5.3. By Country

11. Latin America Biologics Market Analysis and Forecast
11.1. Introduction/Key Findings
11.2. Market Value Forecast By Product , 2016–2026
11.2.1. Monoclonal Antibodies
11.2.2. Vaccines
11.2.3. Recombinant Hormones/Proteins
11.2.4. Cell Therapy
11.2.5. Gene Therapy
11.2.6. Others
11.3. Market Value Forecast By Application , 2016–2026
11.3.1. Oncology
11.3.2. Infectious Diseases
11.3.3. Immunology
11.3.4. Autoimmune Diseases
11.3.5. Others
11.4. Market Value Forecast By Country , 2016–2026
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of LATAM
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Application
11.5.3. By Country

12. MEA Biologics Market Analysis and Forecast
12.1. Introduction/Key Findings
12.2. Market Value Forecast By Product , 2016–2026
12.2.1. Monoclonal Antibodies
12.2.2. Vaccines
12.2.3. Recombinant Hormones/Proteins
12.2.4. Cell Therapy
12.2.5. Gene Therapy
12.2.6. Others
12.3. Market Value Forecast By Application , 2016–2026
12.3.1. Oncology
12.3.2. Infectious Diseases
12.3.3. Immunology
12.3.4. Autoimmune Diseases
12.3.5. Others
12.4. Market Value Forecast By Country , 2016–2026
12.4.1. South Africa
12.4.2. Saudi Arabia
12.4.3. UAE
12.4.4. Rest of MEA
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Application
12.5.3. By Country

13. Competition Landscape
13.1. Market Player – Competition Dashboard (By Tier and Size of companies)
13.2. Blockbuster Drug Matrix
13.3. Pipeline snapshot of Key Biological Therapies
13.4. Company Profiles
13.4.1. AbbVie Inc.
13.4.1.1. Company Overview
13.4.1.2. Financials
13.4.1.3. SWOT Analysis
13.4.1.4. Strategic Overview
13.4.2. Amgen Inc.
13.4.2.1. Company Overview
13.4.2.2. Financials
13.4.2.3. SWOT Analysis
13.4.2.4. Strategic Overview
13.4.3. AstraZeneca
13.4.3.1. Company Overview
13.4.3.2. Financials
13.4.3.3. SWOT Analysis
13.4.3.4. Strategic Overview
13.4.4. Bayer AG
13.4.4.1. Company Overview
13.4.4.2. Financials
13.4.4.3. SWOT Analysis
13.4.4.4. Strategic Overview
13.4.5. Eli Lilly and Company
13.4.5.1. Company Overview
13.4.5.2. Financials
13.4.5.3. SWOT Analysis
13.4.5.4. Strategic Overview
13.4.6. F. Hoffmann-La Roche Ltd.
13.4.6.1. Company Overview
13.4.6.2. Financials
13.4.6.3. SWOT Analysis
13.4.6.4. Strategic Overview
13.4.7. GlaxoSmithKline Plc.
13.4.7.1. Company Overview
13.4.7.2. Financials
13.4.7.3. SWOT Analysis
13.4.7.4. Strategic Overview
13.4.8. Johnson & Johnson Services, Inc.
13.4.8.1. Company Overview
13.4.8.2. Financials
13.4.8.3. SWOT Analysis
13.4.8.4. Strategic Overview
13.4.9. Merck & Co., Inc.
13.4.9.1. Company Overview
13.4.9.2. Financials
13.4.9.3. SWOT Analysis
13.4.9.4. Strategic Overview
13.4.10. Novartis AG
13.4.10.1. Company Overview
13.4.10.2. Financials
13.4.10.3. SWOT Analysis
13.4.10.4. Strategic Overview
13.4.11. Pfizer Inc.
13.4.11.1. Company Overview
13.4.11.2. Financials
13.4.11.3. SWOT Analysis
13.4.11.4. Strategic Overview
13.4.12. Sanofi
13.4.12.1. Company Overview
13.4.12.2. Financials
13.4.12.3. SWOT Analysis
13.4.12.4. Strategic Overview